InvestSMART

Neurizon Therapeutics Limited (ASX:NUZ)

ALERT: Price-sensitive ASX Announcement for NUZ
Current share price for NUZ : $0.085 0.028 (49.12%)+
Announcement
Release
25 Aug 2026 2:58PM
Price at Release
$0.057
Full Release
download
Summary
The 2026 Annual Report for Neurizon Therapeutics Limited covers financial statements and activities for the fiscal year ending 30 June 2026. It includes the consolidated statement of changes in equity, cash flows, financial position, and notes to the financial statements. The report details a significant increase in issued capital, primarily through equity contributions and the issuance of convertible notes. The company reported a comprehensive loss for the year due to substantial net losses after tax, though it managed to raise capital through strategic placements and share-based payments. Despite these losses, Neurizon Therapeutics continues to maintain its operations with a focus on financing through innovative means and meeting its financial obligations.
Key Points
  • Neurizon Therapeutics Limited reported a comprehensive loss for the year ending 30 June 2026.
  • Total equity increased due to contributions of equity and issuance of convertible notes.
  • The company continues to explore financing options through placements and share-based payments.
  • Significant changes in equity were made to offset accumulated losses.
  • Financial highlights include cash flow activities and the impact of R&D tax incentives.
  • The report highlights the conversion of convertible notes into shares.
  • A detailed breakdown of share-based payment transactions is provided in the notes.
  • Neurizon's strategic financing efforts are aimed at sustaining operations despite financial losses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.